Unlock Your Potential with Tieu Equation

The "Tieu Equation" refers to a equation in the field of Quantum Biology, which attempts to  describe how energy is transferred within a biological system by incorporating Quantum Mechanics and temperature, essentially showing how a substance introduced into an organism can generate energy through temperature, leading to particle movement and distribution within the system; it is often represented by the formula:

E = Ȟ |Ψ〉 PT where (E is energy), (Ȟ is the Hamiltonian), (|Ψ〉 is the wave function), (P is the particle), and (T is temperature).

The Tieu Equation is believed to operate based on principles of Quantum Mechanics, where particles can behave like waves, and potentially move through barriers that would be impassable in classical physics.

Tieu Equation + Einstein Equation + Schrodinger Equation = New Innovation Quantum Technology.  The Tieu Equation is a quantum biology that aims to describe how quantum mechanics can be applied to biological systems, the Einstein Equation represents the fundamental relationship between mass and energy, and the Schrodinger Equation is a core equation in quantum mechanics that describes the wave function of a particle, essentially defining its state and behavior at the quantum level.

Tieu Equation is a Quantum Biology, which aims how Particle Becomes Energy = Energy Becomes Mass.

Tieu Equation demonstrates that Quantum Mechanics moves a particle by temperature producing energy thru blood-brain barrier.

Types of Experiments: Cellular Structure and Plant Growth.

Tieu Equation explaining how a substance introduced into high mobility and particle distribution within the organism:

Tieu Equation which helps in cell division and the regeneration of cells promotes the cellular metabolism to return to Homeostasis in the human structure.  It is postulated that in arresting abnormal cellular mutation, enhanced cellular regeneration, and cellular division can be accelerated in relation to the selective existing disease pathology.  It is therefore theorized that the combination of the body's thermal energy, particularly during variance mutation and inflammatory processes, potentiated the self-propelling of molecules by possible passive membrane transportation or passive diffusion of the substance intact across all cell membranes.  This also includes permeation that crosses the blood-brain barrier, which allows its functionality for the central nervous system.  The substance possess a bipolarity and a lipophilicity that facilitates molecular diffusion through various permeable and selective membranes.  In-vivo studies on test subjects have indicated that the cell membrane integrity remains intact and is not disrupted or destroyed in the process of assimilating into the cell, thus ensuring long-term effectiveness on the immune system and cellular metabolism.  They have immune-stimulating properties.  In-vivo studies on treated chronic disease patients indicate increasing phagocytic activity and synthesis of helper cell function.  The substance have shown to transform Deoxyribonucleic acid (DNA) and Ribonucleic acid (RNA) repair, before, during and after chemotherapy drugs, toxic exposure, and chemical induced damage.

Tieu Equation experiments using toxicity tests results on animals and chronic patient medical record results as Real-World Data to generate Real-World Evidence:

Nonclinical Toxicology Results

In the review of the animal studies, it suggests that in a toxic environment that the biological mechanism becomes more efficient and requires less input to function properly, yet the efficiency is improved to the point that the mechanism can even store unused energy for a future need by the mechanism.  This is shown by the increase of body weight by the subject animals.

* Dermal Sensitization Test - Buehler Method; Propose: A Dermal Sensitization test was conducted with guinea pigs to determine the potential for the substance to produce sensitization after repeated topical applications.  The test substance (20% w/w solution in stilled water) was topically applied to ten healthy test guinea pigs and 1-Chloro-2,4-Dinitrobenzene (DNCB, 0.08% in 80% aqueous ethanol) was topically applied to ten  healthy positive control animals, once each week for a three weeks introduction period.  Fourteen days after the last induction dose, a challenge dose of the test or positive control substances at their highest non-irritating concentration (12% w/w solution in distilled water and 0.04% w/w solution in acetone, respectively) was applied to a naive site on each guinea pig from the respective groups.  Approximately twenty-four and forty-eight hours after each induction and challenge dose, the animals were scored for erythema.  Two naive control groups (five animals for the test substance and five for the positive control substance) were maintained under identical environmental conditions and treated with the test or positive control substance at challenge only.  Based on the results of this study, the test substance is not considered to be a contact sensitizer.  The positive response to 0.04% DNCB in acetone validates the test system used in this study.  Conclusion: Based on these findings and on the evaluation, system used, substance is not considered to be contact sensitizer.

* Acute Inhalation Toxicity Limit Test; Purpose: To provide information on health hazards likely to arise from a short term continuous exposure (four hours) to substance via the inhalation route at an exposure level of 2.0 mg/L.  Data from this study may be used as a basis for classification and labeling and/or to select subsequent exposure levels for further studies.  An Acute Inhalation Toxicity test was conducted with rats to determine the potential for substance to produce toxicity via the inhalation route.  Based on the results of this study, the single exposure Acute Inhalation LC50 of the test substance appears to be greater than 2.02 mg/L.  After establishing the desired generation procedures during pre-test trials, ten healthy rats were exposed to the test atmosphere for four hours.  Chamber concentration and particle size distribution of the test substance were determined periodically during the exposure period.  The animals were observed for signs of gross toxicity and behavioral changes at least once daily for fourteen days or until mortality.  Conclusion: This single exposure Inhalation Acute LC50 of substance appears to be greater the 2.02 mg/L when aerosolized as received.

* Genotoxicity; Purpose: The purpose of this study is to evaluate the substance for its ability to induce reverse mutation at the histidine locus in Salmonella Typhimurium tester strains both in the presence and absence of an exogenous mammalian metabolic system (S9) containing microsomal enzyme.  Conclusion: Under the test conditions in this study, the substance was not mutagenic in the tested strains of the Salmonella Typhimurium, histidine auxotrophs TA97, TA98, TA100, TA102, and TA1535 both in the presence and absence of metabolic activation system.  The results indicated that, at the dose concentration of a 25-fold dilution to a 15,625-fold dilution of the original liquid, 100 μl/plate, the substance did not induce point mutations by base substitutions and/or frame shifts in the genome of these tested strains.

Pharmacokinetics

* The substance have produced significant drop in blood sugar levels.  Documented drop in blood sugar has occurred from 440 mg/dL to 60 mg/dL in less than two hours without the patient experiencing any symptoms such as dizziness, weakness, sweating, etc., and still carry on the usual daily activities.  Cancer cell metabolism requires glucose for the fermentation process to produce its energy for growth and development.  This drop in blood glucose arrests the fermentation process and the  cancer cell;

* The substance have affected bone metabolism by demonstrating improved bone density in patient with osteoporotic bone.  Numbers based on densitometry have shown a reversal in L1-L4 from -3.6% to 3.4% in 2-years;

* The subject began taking the substance to help with blood loss.  Operation of surgery results were minimal blood loss of less than 25ml is associated with lower risks of complications;

* The substance has reduced or eliminated jet lag and allowed a normal sleep regiment despite crossing new time zones; and

* Red Blood Cell and Platelet Cell Test Results; Purpose: Patient with Lymphocytic Leukemia is a 69-year-old white male who has been treated for chronic Lynphocytic Leukemia for the last five years.  He started taking substance in October, 2015.  This was because of the concern about falling red blood cell counts and platelet counts.  His white blood cell count, though elevated remained elevated, and fluctuant.  Conclusion: In October, 2015 his red blood cell count was 4.05 and his platelet count was 90.  In April, 2016 his red blood cell count was 4.19 and his platelet count was 105.  It was felt that this was a signification increase in both his red blood cell count and platelet count.